Showing results (1-10 of 39) with videos related to
Sort By:
Pageof 4
Current Oncology Reports|February 17, 2009
Perifosine: update on a novel Akt inhibitorJoell J Gills, Phillip A DennisExpert Opinion on Investigational Drugs|June 24, 2004
The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, AktJoell J Gills, Phillip A DennisCancer Letters|March 17, 2004
Brusatol-induced HL-60 cell differentiation involves NF-kappaB activationMuriel Cuendet, Joell J Gills, John M PezzutoAutophagy|November 15, 2007
Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagyJoell J Gills, Jaclyn Lopiccolo, Phillip A DennisEbiomedicine|October 11, 2019
Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanomaFyza Y Shaikh, Joell J Gills, Cynthia L SearsIn Vivo (Athens, Greece)|January 6, 2021
Combining Nelfinavir With Chloroquine Inhibits <i>In Vivo</i> Growth of Human Lung Cancer Xenograft TumorsJaclyn Lopiccolo, Shigeru Kawabata, Joell J Gills, et al.Cancer Biology & Therapy|February 7, 2004
Targeting aberrant signal transduction pathways in lung cancerJoell J Gills, Courtney A Granville, Phillip A DennisOncotarget|November 21, 2017
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparibAtsushi Osoegawa, Joell J Gills, Shigeru Kawabata, et al.Anti-Cancer Drugs|August 2, 2007
Targeting Akt in cancer therapyJaclyn LoPiccolo, Courtney A Granville, Joell J Gills, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathwayCourtney A Granville, Regan M Memmott, Joell J Gills, et al.Pageof 4